Literature DB >> 26399488

Incidence, risk factors, and dose-volume relationship of radiation-induced rib fracture after carbon ion radiotherapy for lung cancer.

Takanori Abe1, Katsuyuki Shirai1, Jun-Ichi Saitoh1, Takeshi Ebara2, Hirofumi Shimada3, Mutsumi Tashiro3, Naoko Okano1, Tatsuya Ohno3, Takashi Nakano1.   

Abstract

BACKGROUND: The purpose of this study was to assess the incidence, risk factors, and dose-volume relationship of radiation-induced rib fracture (RIRF) after carbon ion radiotherapy for lung cancer.
MATERIAL AND METHODS: Fifty-seven ribs of 18 patients with peripheral stage I non-small cell lung cancer treated with carbon ion radiotherapy were analyzed on rib fracture. The patients were treated at a total dose of 52.8 Gy [relative biologic effectiveness (RBE)] or 60.0 Gy (RBE) in 4 fractions and were followed at least six months. Patient characteristics and dosimetric parameters were analyzed for associations with RIRF.
RESULTS: Eighteen patients and 57 ribs were included in this study. The median length of follow-up was 36.5 months. RIRF was observed in seven (39%) of the 18 patients, and in 11 (19%) of 57 ribs. Only one patient developed symptomatic fracture. The distance from the ribs to the tumor site was significantly shorter in fractured ribs than in non-fractured ribs (1.4 ± 0.3 cm vs. 2.5 ± 0.3 cm). Receiver operating characteristic curve analysis showed that [Formula: see text] as a cut-off value for discriminating RIRF had the largest area under the curve (AUC =0.78). Comparison of the two-year cumulative incidence of RIRF among two groups as determined by cut-off values, yielded the following result: 53% vs. 4% [[Formula: see text], ≥ 38.2 Gy (RBE) or less]. Results from the two groups were significantly different (p < 0.05).
CONCLUSION: The crude incidence of RIRF after carbon ion radiotherapy was 39% but incidence of symptomatic fracture was low. The [Formula: see text] as cut-off values may be helpful for discriminating the risk of RIRF.

Entities:  

Mesh:

Year:  2015        PMID: 26399488     DOI: 10.3109/0284186X.2015.1088169

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  1 in total

1.  Knockdown of CENPF inhibits the progression of lung adenocarcinoma mediated by ERβ2/5 pathway.

Authors:  Tang Hexiao; Bai Yuquan; Xiong Lecai; Wei Yanhong; Shen Li; Hu Weidong; Xu Ming; Zhou Xuefeng; Pan Gaofeng; Zhang Li; Zhu Minglin; Tang Zheng; Yang Zetian; Zhou Xiao; Cai Yi; Michael Lanuti; Zhao Jinping
Journal:  Aging (Albany NY)       Date:  2021-01-10       Impact factor: 5.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.